By comparison, a study investigating genetic mutation testing for epidermal growth factor receptor (EGFR) in the USA, found that in AI/AN cases and non-AI/AN controls both diagnosed with adenocarcinoma, about one-third of the participants received EGFR testing with no significant difference in testing between the two groups [35]. This evidence concerns the gene EGFR and adenocarcinoma.